bioRxiv · 10.1101/2021.02.01.429108
Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite a lack of an antiviral effect
Abstract
In response to the ongoing COVID-19 pandemic, repurposing of drugs for the treatment of SARS-CoV-2 infections is being explored. The HIV protease inhibitor Nelfinavir, widely prescribed in combination with other HIV inhibitors, has been shown to inhibit in vitro SARS-CoV-2 replication. We here report on the effect of Nelfinavir in the Syrian hamster SARS-CoV-2 infection model. Although treatment of infected hamsters with either 15 or 50 mg/kg BID Nelfinavir [for four consecutive days, initiated on the day of infection] does not reduce viral RNA loads nor infectious virus titres in the lungs compared to the vehicle control, the drug reduced virus-induced lung pathology to nearly the baseline scores of healthy animals. A substantial interstitial infiltration of neutrophils is observed in the lungs of treated (both infected and uninfected) animals. The protective effect of Nelfinavir on SARS-CoV-2-induced lung pathology (at doses that are well tolerated and that result in exposures nearing those observed in HIV-infected patients) may lay the foundation for clinical studies with this widely used drug.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Foo, C. S., Abdelnabi, R., Kaptein, S. J. F., Zhang, X., ter Horst, S., Mols, R., Delang, L., Rocha-Pereira, J., Coelmont, L., Leyssen, P., Dallmeier, K., Vergote, V., Heylen, E., Vangeel, L., Chatterjee, A. K., Annaert, P., Augustijns, P., De Jonghe, S., Jochmans, D., Weynand, B., Neyts, J.. 2021-02-01. Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite a lack of an antiviral effect. https://doi.org/10.1101/2021.02.01.429108
Cite the original work for its findings. Save a collection to share your selection of sources.